Incidence of bleeding after minor oral surgery in patients on dual antiplatelet therapy: a systematic review and meta-analysis.

Bleeding is a feared complication of minor oral surgery in patients on treatment with antiplatelet agents and there is no agreed strategy regarding the cessation or not of antiplatelet treatment. The aim of this systematic review was to evaluate bleeding with minor oral surgery in patients on dual antiplatelet therapy (DAPT), single antiplatelet therapy (SAPT), or no antiplatelet therapy (no APT). The PubMed, Embase, Web of Science, and Cochrane Library databases were screened. Sixteen studies were included. DAPT was continued in all studies. The perioperative bleeding risk was significantly higher for DAPT than for SAPT (risk ratio (RR) 10.16, P= 0.010; risk difference (RD) 0.35, P= 0.269), but not higher compared to no APT (RR 6.50, P= 0.057; RD 0.19, P= 0.060). The postoperative bleeding risk was significantly elevated for DAPT compared to SAPT (RR 2.61, P= 0.010) and no APT (RR 3.63, P= 0.035), but only by 1% (RD 0.01, P= 0.103) and 1% (RD 0.01, P= 0.421), respectively. Clinically, this may be considered quite similar. Additionally, local haemostatic measures could control all reported bleeding and no lethal events occurred. Therefore, DAPT interruption is not advised before minor oral surgery.

Tranexamic acid to reduce bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants: design and rationale of the EXTRACT-NOAC trial.

Bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants (NOAC) may lead to unplanned reinterventions and interruption of anticoagulation, thereby exposing patients to a risk of thromboembolism. We have designed a study (EXTRACT-NOAC) to investigate whether tranexamic acid (TXA) mouthwash decreases bleeding after extraction in such patients. The study is a randomised, double-blind, placebo-controlled trial. We plan to randomise 236 patients listed for dental extraction and treated with NOAC to 10% TXA mouthwash or placebo. Patients are instructed to use the mouthwash before the dental extraction, and three times a day for three days thereafter. The primary outcome is oral bleeding. Secondary outcomes include type of bleeding, procedural bleeding score, number of reinterventions after oral bleeding, and number of interruptions in NOAC treatment. Any bleeding from sources other than the mouth, and thrombotic events, are recorded as safety outcomes. Patients are followed-up for seven days. This study will provide evidence to guide the management of patients taking NOAC who need teeth extracted.

Anatomical relation of third molars and the retromolar canal.

The study was designed to assess, by direct anatomical observations and cone-beam computed tomography (CT), the prevalence of a retromolar canal and foramen in relation to the mandibular third molar in dry human mandibles. Dry mandibles from European skeletons (n=89) were observed directly and after cone-beam CT scanning (Newtom VGI evo). The following variables were assessed: the presence of a retromolar foramen and canal; the presence of a third molar, and orientation of the third molar. From the total of 89 mandibles selected, 73 showed a retromolar foramen (49 of which were bilateral). A retromolar canal was identified in 64 mandibles based on cone-beam CT assessment, with a total of 101 canals, including 74 that were bilateral. A total of 112 hemimandibles contained a third molar. Orientation of the third molar did not seem to indicate the presence of retromolar foramina or canals. A similar prevalence of retromolar canals was found for both vertically (41/79) and mesially (17/33) orientated third molars. A retromolar foramen and canal were present in most mandibles, with more than half being bilateral. We were unable to confirm a potential relation between the retromolar foramen and canal on the one hand, and the orientation of the third molar on the other.